Abstract: In one aspect, the present disclosure provides for novel compositions of matter comprising multi domain peptide (MDP) hydrogels and cyclic dinucleotides (CDNs). Also disclosed are method of using such compositions in the treatment of cancer, including in particular the treatment of head and neck cancers, such as those resistant to CDN therapy.
Type:
Grant
Filed:
June 15, 2018
Date of Patent:
April 30, 2024
Assignees:
William Marsh Rice University, The Board of Regents of The University of Texas System
Inventors:
Simon Young, David Leach, Jeffrey D. Hartgerink
Abstract: The present invention relates to novel peptide antagonists that inhibit binding of acetylcholine to the active site of the muscle-type nicotinic acetylcholine receptor. The peptide antagonists of the invention are useful in cosmetic compositions that prevent or improve the appearance of skin wrinkles and related skin conditions. The invention further relates to cosmetic and pharmaceutical compositions comprising a peptide antagonist of the invention, and methods for their use.
Abstract: Methods for treating non-alcoholic steatohepatitis and/or hepatocellular carcinoma include administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof. Methods and assays for diagnosis or prognosis of non-alcoholic steatohepatitis and/or hepatocellular carcinoma in a subject are also provided and include the steps of providing a biological sample from the subject, determining an expression level or activity in the sample of at least one biomarker selected from Caveolin-1, Survivin, and SMAC; and comparing the expression level or activity of the at least one biomarker in the sample, if present, to a control expression level or activity of the at least one biomarker. Prophylaxis or treatment of the non-alcoholic steatohepatitis and/or hepatocellular carcinoma in a subject can then be initiated based on the expression level or activity of Caveolin-1, Survivin, and SMAC in the sample.
Type:
Grant
Filed:
April 6, 2021
Date of Patent:
April 16, 2024
Assignee:
MARSHALL UNIVERSITY RESEARCH CORPORATION
Inventors:
Juan Sanabria, Sandrine Pierre, Moumita Banerjee, Zijian Xie, Joseph Shapiro
Abstract: The present invention relates to, in part, methods of improved healthcare in female subjects that, for example, rely on menstrual fluid sampling for applying selection biomarkers.
Abstract: The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
Abstract: Provided herein are integrin antagonists and methods of using the same. For example, one or more of the compounds or polypeptides provided herein can be used in the treatment of disorders such as heart attacks, stroke, and cancer metastasis.
Abstract: Compounds represented by formula (I) can be used to make antibody-drug conjugates. The conjugates so made are stable in both human and mouse serum, enabling the performance of pre-clinical studies using a mouse model.
Abstract: Systems and methods for acquiring, preserving, and administering delipidated plasma. Extracted delipidated plasma, comprising pre-beta HDL, is obtained and are spot tested to establish baseline amounts or concentrations of pre-beta HDL. The batches are subjected to preservation, stored, and then prepared again for use at some later date. A portion of the batch may be tested again to determine if the pre-beta HDL in the delipidated plasma has degraded or is no longer effective.
Type:
Grant
Filed:
May 10, 2021
Date of Patent:
February 20, 2024
Assignee:
HDL Therapeutics, Inc.
Inventors:
Hollis Bryan Brewer, Jr., Michael M. Matin
Abstract: This invention relates to methods of administering oral octreotide therapy to a female subject relating to avoidance of combined oral contraceptives or use of a back-up method for contraception.
Type:
Grant
Filed:
September 9, 2021
Date of Patent:
February 6, 2024
Assignee:
Amryt Endo, Inc.
Inventors:
Asi Haviv, Ruth Engle Stevens, Jennings Ray Dawkins
Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus and/or C-terminus contains an added component that improves (1) the peptide's solubility at physiological pH; (2) the peptide's plasma half-life; (3) the peptide's intraocular retention; and/or (4) the peptide's binding affinity to C3 or its fragments as compared to an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.
Type:
Grant
Filed:
April 5, 2019
Date of Patent:
January 30, 2024
Assignee:
The Trustees of the University of Pennsylvania
Abstract: The present invention relates to a two-part linker comprising a peptide tag (peptide) and a polypeptide (protein) that is capable of spontaneously forming an isopeptide bond, particularly wherein: a) said peptide comprises an amino acid sequence as set forth in SEQ ID NO: 1, wherein: (i) X at position 1 is arginine or no amino acid; (ii) X at position 2 is glycine or no amino acid; (iii) X at position 5 is histidine or threonine; (iv) X at position 11 is alanine, glycine or valine; and (v) X at position 14 is arginine or lysine, wherein when X at position 1 is no amino acid, X at position 2 is no amino acid; and b) said polypeptide comprises: i) an amino acid sequence as set forth in SEQ ID NO: 2; ii) a portion of (i) comprising an amino acid sequence as set forth in SEQ ID NO: 101; iii) an amino acid sequence with at least 80% sequence identity to a sequence as set forth in SEQ ID NO: 2, wherein said amino acid sequence comprises a lysine at position 34, a glutamic acid at position 80 and one or more of the
Abstract: To provide a novel pharmaceutical use of a peptide. A pharmaceutical composition for the treatment or prevention of retinitis pigmentosa, comprising a peptide which comprises the amino acid sequence shown in SEQ ID NO: 30 and inhibits the protease activity.
Abstract: Anticachexin C1 inhibits the TNF?-TNF? receptor interaction. In this work, analogs of anticachexin C1 are disclosed. The resulting bicyclic peptides inhibit TNF? TNF?-induced cell death, NF-?B activation, and c-Jun N-terminal kinase (JNK) signaling in cultured mammalian cells. Methods of using the bicyclic peptide anticachexin C1 analogs to treat cancer, inflammatory disorders and immune disorders are also described.
Abstract: The present invention provides certain lipo-glycopeptide cleavable derivatives and methods for using the same for the treatment of bacterial infections, for example, pulmonary bacterial infections. The LGPC derivatives include a cleavable moiety that in certain embodiments, is designed to allow for cellular uptake and/or a more rapid clearance of the glycopeptide metabolite (i.e., the cleaved glycopeptide) from the site of administration (e.g., the lung) as compared to the uncleaved LGPC.
Type:
Grant
Filed:
June 10, 2021
Date of Patent:
January 2, 2024
Assignee:
Insmed Incorporated
Inventors:
Ryan Heckler, Donna Konicek, Adam Plaunt, Vladimir Malinin, Walter Perkins
Abstract: The present invention provides a method for treating and/or ameliorating a disorder of the lower urinary tract, comprising administering a composition comprising a glucagon like peptide 2 (GLP-2) receptor agonist to a patient in need thereof in an amount sufficient to treat and/or ameliorate the disorder of the lower urinary tract.
Type:
Grant
Filed:
January 20, 2021
Date of Patent:
December 26, 2023
Inventors:
Christopher P. Meenan, C. Lowell Parsons, Daniel Vickery
Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.
Abstract: Provided herein are newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers. Additionally, methods of storing and treating with abaloparatide in view of the newly discovered abaloparatide isomers are described.
Type:
Grant
Filed:
October 21, 2022
Date of Patent:
December 5, 2023
Assignee:
Radius Health, Inc.
Inventors:
Greg Williams, Naveen Palwai, David Hanley
Abstract: The present disclosure provides conjugates that comprise an insulin molecule conjugated via a conjugate framework to two or more separate ligands that each include a saccharide, wherein the framework, ligand, saccharide and insulin molecule optionally comprise a fatty chain (e.g., a C8-30 fatty chain), wherein when said insulin molecule is conjugated both to a C8-30 fatty chain and one or more separate ligands that each include a saccharide, said C8-30 fatty chain is linked to insulin molecule only, and wherein when the framework or ligand comprises a fatty chain the insulin molecule is conjugated to two or more separate ligands. In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile.
Type:
Grant
Filed:
December 13, 2018
Date of Patent:
November 21, 2023
Assignee:
MERCK SHARP & DOHME LLC
Inventors:
Lin Yan, Pei Huo, Ahmet Kekec, Danqing D. Feng, Yuping Zhu, Dmitri Pissarnitski, Chris Moyes, Songnian Lin
Abstract: The present invention provides a polypeptide capable of crossing the blood-brain barrier. In the present invention, C-terminal of the ziconotide is linked to N-terminal of a cell membrane penetrating peptide via one glycine to obtain a polypeptide capable of crossing the blood-brain barrier. The polypeptide of the present invention is suitable for intravenous, intraperitoneal or nasal administration with convenient operation and low clinical risk. It has a long pharmacological effect in vivo, excellent analgesic effect, and slight peptide side effect after intravenous, intraperitoneal or nasal administration, and is suitable for large-scale clinical applications. The polypeptide of the invention has the advantages of simple preparation, controllable preparation process and quality during the preparation, and is suitable for large-scale industrial production.
Type:
Grant
Filed:
December 27, 2018
Date of Patent:
November 14, 2023
Assignee:
SHENZHEN RUIJIAN BIOSCIENCE TECHNOLOGY LIMITED COMPANY